Abstract This study investigated in a healthy population (n=220) the association of the Taql B restriction fragment length polymorphism (RFLP) in the cholesteryl ester transfer protein (CETP) gene with plasma high-density lipoprotein (HDL) cholesterol concentration and subfraction distribution. A raised HDL cholesterol level was found in B2B2 homozygotes (B2 cutting site absent) and was associated specifically with a 45% increase in HDL 2 compared with B1B1 homozygotes (B1B1, 77±39 mg/100 mL, mean±SD; B2B2, 112±59 mg/100 mL; / > <0.01). Total plasma, very-low-density lipoprotein, and HDL triglyceride levels did not differ among the genotype groups, nor did plasma apolipoprotein AI levels {B1B1, 1.45+0.35 mg/mL, mean±SD; B2B2, 1.56±0.33 mg/ mL). Thus, the genetic variation appeared to be independent of metabolic factors that are known to regulate HDL levels. Plasma CETP exchange activity was unlikely to be the cause of L ow plasma levels of high-density lipoprotein (HDL) are associated with increased coronary artery disease risk.
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1 -2 In addition, it has been found that clinical benefit is associated with a rise in HDL concentration in intervention trials. The Helsinki Heart Study 3 showed that a mean increase of 11% in HDL cholesterol levels was associated with a 34% reduction in coronary heart disease even after correction for other risk factors, including low-density lipoprotein (LDL) cholesterol and plasma triglyceride levels.
Plasma HDL is composed of two main subfractions, HDL 2 (1.063<d<1.125 g/mL) and HDL 3 (1.125<rf< 1.21 g/mL), and it is the former that is particularly associated with protection from coronary artery disease. 4 The strong inverse correlation between triglyceride concentration and HDL concentration 5 and HDL size in normal individuals 6 is thought to be due to triglyceride transfer from very-low-density lipoprotein (VLDL) and chylomicrons to HDL, with subsequent the association, since it did not differ between genotype groups and was not correlated with HDL 2 concentration. Multivariate analysis demonstrated that the Taql B polymorphism had an effect on HDL cholesterol and HDL 2 that was independent of age, sex, body mass index, oral contraceptive use, exercise, alcohol consumption, and plasma triglycerides. In smokers, the presence of the B2B2 genotype did not result in increased HDL cholesterol or HDL 2 , whereas in obese subjects, the difference between B1B1 and B2B2 individuals was diminished. We conclude that the Taql B RFLP is associated with a quantitatively significant effect on plasma HDL 2 levels that is independent of plasma triglycerides and interacts with lifestyle factors. (Arterioscler Thromb. 1994;14:336-344.)
Key Words • cholesteryl ester transfer protein • HDL • restriction fragment length polymorphisms • smoking • triglycerides shrinkage of the HDL particle by the action of hepatic lipase. 7 - 8 In coronary artery-diseased patients, however, although HDL 2 levels are reduced, the relation between HDL and plasma triglyceride is lost; this suggests that other mechanisms, independent of the aforementioned triglyceride exchange, may be responsible for the reduced HDL level. 9 In this regard, it has been reported that HDL concentration and subfraction distribution are altered by environmental factors, 1011 including cigarette smoking, alcohol intake, physical activity, and obesity. In a study of normal individuals, 5 we provided evidence that the marked difference in plasma HDL levels between smokers and nonsmokers was apparently the result of both triglyceride-dependent and triglyceride-independent mechanisms.
Several restriction fragment length polymorphisms (RFLPs) in the cholesteryl ester transfer protein (CETP) gene have been detected. 1214 One of these, a site polymorphic for the presence or absence of a Taql restriction site, has been shown by us 15 and by other groups' 6 to be associated with high plasma HDL concentrations. Individuals homozygous for the absence of a Taql restriction cutting site, ie, B2B2 individuals, have a higher HDL concentration than those homozygous for the presence of the restriction site. This was found in both a random sample of normal subjects 16 - 17 and a population selected according to whether they had high or low HDL levels. 15 In the latter group, higher HDL levels were also associated with a lower plasma CETP activity, an enzyme that is thought to be involved in the metabolism of plasma HDL, raising the possibility that variation in the enzyme was the underlying effect. A further observation from the study of Kondo et al 16 was that the association of the Taql B polymorphism with apolipoprotein Al levels was present in nonsmokers but not in smokers. They found no significant effect of Taql B RFLP on HDL cholesterol in nonsmokers, but they did note a trend.
The aim of this cross-sectional study was to establish the nature of the association of the Taql B polymorphism with plasma HDL cholesterol, subtraction distribution, and apolipoprotein Al in a healthy population. We addressed specifically the potential role of plasma CETP activity in the mechanism. Cigarette smoking and other environmental factors were assessed to determine whether there was an interaction between environment and the genetic influence on plasma HDL concentration.
Methods Subjects
The population was drawn from normal, healthy volunteers attending three health centers in Strathclyde and from healthy hospital staff at Glasgow Royal Infirmary. Subjects, under nurse supervision, completed a lifestyle questionnaire and donated a 50-mL blood sample after a 12-hour fast. The questionnaire asked for information on smoking status and alcohol consumption. At the time of blood donation, height and weight (without shoes) were measured, as was blood pressure. Body mass index (BMI) was calculated as weight (kg)/height (m) squared. Routine analyses for urea, electrolytes, and glucose; liver function tests; and thyroid hormone assays were performed to exclude underlying causes of dyslipidemia. Total cholesterol, VLDL cholesterol, LDL cholesterol, and HDL cholesterol were measured, and hyperlipidemic individuals were eliminated from analysis if they had an LDL cholesterol value of >6.0 mmol/L or a plasma triglyceride value of >3.0 mmol/L. Subjects with raised liver enzymes or a thyroid-stimulating hormone level of >5.0 mU/L in combination with a low circulating triiodothyronine or thyroxine were also excluded. Ethical approval for the study was granted by the Ethics Committee of the Glasgow Royal Infirmary.
Plasma Lipids and Lipoproteins
Lipid and lipoprotein measurements were performed using a modification of the Lipid Research Clinics Program protocol. 18 The HDL subfraction distribution was determined by two techniques: analytical ultracentrifugation (Beckman L-8 with optical scanning unit; Beckman, High Wycombe, UK), which gave concentration values for HDL 2 and HDL, 19 ; and nondenaturing gradient gel electrophoresis (4% to 30%, Pharmacia Biotech Ltd, Milton Keynes, UK), which gave the percent distribution of HDL a (particle diameter, 9.7 to 12.9 nm), HDLj, (8.8 to 9.7 nm), HDL,. (8.2 to 8.8 nm), and HDLj, tt (7.2 to 8.2 nm) after video densitometric scanning (Bio-Rad 620 video densitometer, Bio-Rad Laboratories Ltd, Herts, UK). 20 In the latter technique, concentrations were estimated by multiplying percent abundance of each fraction by the total HDL concentration determined by ultracentrifugation. It has previously been shown that differences in chromogenicity of the HDL subfractions account for less than 7% of the variation in the particle concentration. 21 Apolipoprotein Al was measured by immunoturbidimetry (Orion Diagnostics catalog No. 67 265).
Enzyme Assays
Plasma CETP activity was measured in a 1/100 or 1/50 dilution of plasma according to the method of Freeman et al. 15 The assay was based on the exchange of cholesteryl ester between exogenous substrates, radiolabeled 'H-CE-HDL,, and an LDL/VLDL mixture. Concentrations of donor (0.5 mg/mL protein) and acceptor (0.8 mg/mL protein) particles were such as to reveal maximal transfer activity. Activity was expressed as percent transfer of cholesteryl ester per microliter plasma (in 2.5 hours). The interassay coefficient of variation was <10%.
Southern Blot Analyses
DNA was prepared from blood lymphocytes by the method of Kunkel et al. 22 RFLP detection was performed using standard methods. 23 Taql A and Taql B restriction polymorphisms were detected using a 1581-bp complementary DNA CETP clone, 12 which was a gift from Dr D. Drayna (Genentech Inc, San Francisco, Calif.).
Statistical Analyses
Statistical manipulations and sample difference testing were carried out using the MINITAB computer program (version 8, 1991, Minitab Inc, State College, Pa). Data were tested for normality using normal probability plots and, if necessary, transformed to produce a normal distribution. Plasma triglycerides, VLDL triglycerides, HDL cholesterol, HDL 2 , apolipoprotein Al, HDLa,, HDLa+c, and BMI values were transformed to their log 10 values, whereas VLDL cholesterol and alcohol consumption were normalized by taking the square root. Differences among genotypes were tested on transformed data using one-way ANOVA. Differences between groups at the extremes of the distribution were tested with a two-sample t test. Difference in distribution was assessed by x 2 test. The independent contributions of genotype, age, sex, BMI, smoking, alcohol consumption, and triglyceride to HDL and HDL subfraction concentrations were assessed using the general linear model within MINITAB. Adjustment of HDL concentration for confounding factors was carried out using the general linear model. For the multivariate analysis, smoking status was defined as either current smoker or nonsmoker, which comprised those who had never smoked as well as exsmokers who had stopped smoking for more than 1 year. The bimodality of HDL distributions was assessed using a test for clusters.
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Results
Population Description
Demographic data for the population (n=220) studied are shown in Table 1 . The frequencies for the Taql Bl allele and the Taql B2 allele were 0.54 and 0.46, respectively. These values are in good agreement with previously reported frequencies, 12 - 16 and the polymorphism was shown to be in Hardy-Weinberg equilibrium. The genotype groups were well matched with respect to age, sex, and lifestyle factors (BMI, alcohol consumption, cigarette smoking, and degree of exercise). Individuals were categorized as "actively engaged in exercise" if they intimated on the lifestyle questionnaire that they participated in sports and were conscientious exercizers.
Lipid Parameters
Plasma total cholesterol and total, VLDL, and HDL triglycerides were similar in the different genotypes (Table 2) . HDL cholesterol levels were significantly higher in B2B2 individuals than in B1B1 individuals (P<.005), while B1B2 heterozygotes had an intermediate HDL cholesterol level. There was also a nonsignificant trend toward higher apolipoprotein Al in the B2B2 homozygotes. There was no overall difference in 18 BMI indicates body mass Index. Means±SDs are shown; (geometric means±SDs) are shown for transformed data. Differences among the three groups were tested by ANOVA (on transformed data if required). The difference in sex and exercise distribution among the groups was tested using a * 2 test.
plasma CETP activity among the genotypes (ANOVA), but activity was marginally higher in the B1B2 heterozygotes (P<.05, two-sample t test) than in B1B1 homozygotes and the same as that seen in B2B2 homozygotes.
HDL Subtractions
The difference in plasma HDL cholesterol levels was associated with a specific increase in HDL 2 in the B2B2 group as detected by analytical ultracentrirugation (Table  3) . B2B2 homozygotes had 45% higher HDL 2 levels than B1B1 homozygotes (P<.01), with the heterozygous group showing intermediate levels. When HDL subtraction distribution was assessed using gradient gel electrophoresis, the HDLa subtraction was significantly raised (54%) in the B2B2 group (P<.05). There were no differences among the groups in HDL3 subtraction concentrations detected by analytical ultracentrifugation, but HDL3, was marginally reduced (11%) in B1B2 heterozygotes.
A number of lifestyle factors had an impact on HDL cholesterol and HDL 2 levels. Multivariate analysis revealed that age, sex, BMI, alcohol consumption, and smoking were independent explanatory variables whose association with HDL cholesterol and HDL 2 persisted even when plasma triglyceride was included in the model (Table 4 ). The Taql B polymorphism also had an independent effect on plasma HDL cholesterol (P<.01) and HDL 2 (P< .02) that was similar in magnitude to that of smoking.
Interaction of Smoking and Taql B Genotype
The subjects were divided into groups according to their Taql B genotype and smoking status (Table 5) . tP<.05, different from ±P<.01, different from Differences among the three groups were tested by ANOVA (on transformed data If required). Differences were tested by using a two-sample f test (on transformed data if required). HDL 2 and HDL, were determined by analytical ultracentrifugation on 215 of 220 subjects. HDLa,, HDLa, HDLJ., and HDLa, +0 were determined by gradient gel electrophoresis on 114 of the 220 subjects.
B2B2
Smokers were individuals who were currently smoking, and nonsmokers were those who had never smoked. Exsmokers were a heterogeneous gTOup who had smoked in the past but at the time had stopped for a period ranging from less than 1 year up to 25 years. The association of the Taql B2 restriction site with high HDL indicates high-density lipoprotein; BMI, body mass index; and RFLP, restriction fragment length porymorphlsms. *Ps.O5; tPs0.2; #><;.O1; §Ps.0O5; and |Ps.OO1. For multivariate analysis, the general linear model was used to examine the independent effects of sex, age, BMI (log), alcohol consumption (square root), plasma triglyceride (tog), smoking, and Taq\ B RFLP on plasma HDL cholesterol (log) and HDL 2 (log). Percent contribution to the variation (adjusted means squared, divided by the total means squared, expressed as a percentage) is quoted along with the level of significance. Individuals were categorized as smokers or nonsmokers. Exsmokers who had stopped smoking for more than 1 year were classified as nonsmokers. HDL and HDL 2 were higher in women than in men and negatively associated with BMI, plasma triglycerides, and smoking. HDL was marginally positively associated with alcohol consumption and age, whereas HDL 2 was marginally negatively associated with these variables.
HDL levels was only observed in the nonsmoker (P<.05) and exsmoker (P<.05) groups. There was no difference between B1B1 smokers' and B2B2 smokers' HDL cholesterol. This pattern was maintained after plasma HDL concentrations were corrected for sex, age, BMI, alcohol consumption, and plasma triglyceride using a general linear model (Table 5 ) (smokers B1B1 versus B2B2, not significant; nonsmokers B1B1 versus B2B2, P<.005). Within each genotype, there was a trend toward higher HDL cholesterol levels in nonsmokers, but this was only significant for the B2B2 group.
Interaction of Other Lifestyle Factors With Taql B Genotype
The population was divided according to sex, tertile of age, tertile of BMI, tertile of alcohol consumption, oral contraceptive use, or exercise habit. Each factor was assessed for its interaction with the Taql B-associated influence on HDL. Only BMI showed an effect in the whole group (data not shown), and it was similar to that observed for smoking. Because there was no effect of genotype on HDL levels in smokers, the analysis was also restricted to nonsmokers (Table 6 ), comprising those who had never smoked as well as exsmokers who had stopped smoking for more than 1 year. When nonsmokers were divided into groups according to Taql B genotype and tertile of BMI, it was seen that homozygotes for the B2 site had significantly higher HDL than B1B1 homozygotes if they were relatively lean (lowest BMI tertile, P<.05), but not if they had a higher BMI. A substantial (0.36 mmol/L) difference in the lowest BMI tertile was maintained after adjustment of HDL cholesterol for sex, age, alcohol consumption, and plasma triglyceride. In the highest BMI tertile, on adjustment for confounding factors, the difference in HDL levels between the Taql B genotypes was smaller and not significant (0.17 mmol/L). In all genotypes, individuals in the lowest BMI tertile had higher HDL levels than those in the highest BMI tertile, but this difference was no longer significant after correction of HDL for confounding factors. The general linear model (MINITAB, version 8) was used to test for interaction between Taql B genotype, smoking, and obesity. There was no significant interaction between Taql B genotype and smoking when subjects were divided into the three categories of smokers, exsmokers, and nonsmokers. However, if exsmokers who had stopped smoking for more than 1 year were reclassified as nonsmokers and exsmokers who had stopped smoking for less than 1 year (n=4) were excluded, then there was weak evidence (P=.O6) for an interaction between smoking and Taql B genotype. The smoker B1B1/B2B2 difference in plasma HDL concentration was 0.01 mmol/L and the nonsmoker difference 
Frequency Distributions of HDL Cholesterol by Genotype
The frequency distribution of HDL cholesterol in the three Taql genotypes was determined in a combined group of nonsmokers plus those exsmokers who had stopped for more than 1 year. The Figure (A) shows that the distribution did not depend on the sex of individuals in the group, and it was also independent of BMI (B). Distributions of men and women or individuals with BMI greater than or less than the median were not different among the genotypes (not significant by x 2 test). It can be seen from these histograms that the distribution of HDL cholesterol in B1B1, B1B2, and B2B2 individuals is different. HDL cholesterol in B1B1 homozygotes is distributed between 0.9 mmol/L and 1.8 mmol/L, with a median of 1.38 mmol/L. Only three individuals have an HDL cholesterol level of >1.6 mmol/L. The distribution of the B1B2 individuals covered the whole range of HDL cholesterol but appeared to be bimodal, with one population distributed around 1.4 mmol/L and the other distributed around 1.8 mmol/L. In this genotype, 75% of individuals had an HDL cholesterol is 1.6 mmol/L, and 25% had HDL cholesterol > 1.6 mmol/L. The numbers of individuals in the B2B2 group were too low to discern whether the distribution was bimodal; however, 52% of individuals had HDL cholesterol ^1.6 mmol/L, and 48% had an HDL cholesterol of >1.6 mmol/L. A x 2 test demonstrated that there was a significant difference (f<.005) in the distribution of HDL cholesterol levels above and below 1.6 mmol/L across the Taql B genotypes.
To test whether the population demonstrated a bimodal distribution of HDL cholesterol, a test for clusters 24 -25 was used with critical values for the population size in question computed by simulation. Using this analysis, we were unable to demonstrate whether the B1B2 nonsmoking population was bimodal.
Discussion
In the population under study, the Taql B RFLP of the CETP gene was associated with variation in plasma HDL cholesterol concentrations. This confirms the trend reported by Kondo et al 16 in Norwegian individuals and by our own previous study where subjects were selected on the basis of a high or low HDL level. 15 Two studies 26 -27 found weak or no evidence for an association between Taql B genotype and HDL. However, in one study, 26 an association did become apparent when nonsmokers only were analyzed. In the other study, 27 no information on smoking was available for the control population, and in the hyperlipidemic population, accounting for smoking did not reveal any association between Taql B genotype and HDL. It is possible that any association between the two parameters may not be evident in all genetic populations and may be affected by hyperlipidemia. In the present study, individuals homozygous for the absence of the Taql B restriction site (B2B2) had significantly and substantially higher HDL cholesterol than those homozygous for its presence (B1B1). The 0.24-mmol/L difference ( Table 2) represents 30% of the reference range for our local population (1.0 to 1.8 mmol/L). The difference in HDL concentration was associated specifically with a higher HDL 2 , and when subtractions were analyzed on the basis of their particle size distribution, it could be seen that the 35 mg/100 mL difference in plasma HDL 2 was explained predominantly by a 36 mg/100 mL difference in the largest HDL subtraction, HDLa, (P<.05).
Our initial hypothesis was that the Taql B-dependent variation was mediated by changes in plasma CETP activity. However, in contrast to our previous study in highly selected populations, we saw no association between the Taql B genotype, plasma CETP activity, and HDL cholesterol. In the present study, CETP activity was found to be marginally lower in B1B1 individuals, the group of individuals associated with low plasma HDL concentration. This effect is opposite to that which might be expected from previous reports of an inverse relation between HDL and plasma CETP activity. However, we 5 and other investigators 28 have shown that there is no correlation between plasma HDL concentration and CETP activity within a normal population, although a weak correlation has been found with CETP mass. 29 It is possible that a strong relation between these two parameters is only evident in extreme cases of CETP variation, eg, familial hyperalphalipoproteinemia, 30 or between species. 31 In our previous study, in which differences in genotype and plasma CETP activity between two groups selected according to high or low HDL levels 15 were studied, our high-HDL group may have contained a subpopulation of individuals who were hyperalphalipoproteinemic with accompanying low CETP activity; consequently, this lowered the mean CETP activity for the high-HDL population as a whole. On the basis of the current data, we surmise that CETP activity per se is not responsible for the association between the Taql B RFLP and HDL. It is possible that mutations in the CETP gene may affect substrate specificity, and such a phenomenon has been identified for the lipoprotein lipase gene. 32 The CETP assay used here measured CETP activity and would have been unable to detect differences in substrate specificity.
In an attempt to investigate this further, we studied the possible role of variation in plasma triglycerides, which are known to be important in determining HDL 2 and HDL3 concentrations. No significant difference in plasma total, VLDL, or HDL triglycerides was observed among the Taql B genotype groups. Furthermore, multivariate analysis using a general linear model demonstrated that the contribution of the polymorphism to variation in HDL cholesterol was independent of triglyceride; after accounting for the confounding effects of age, sex, BMI, alcohol consumption, and plasma triglyceride, the Taql B RFLP was still a significant (P<.01) explanatory variable for plasma HDL cholesterol and HDL 2 (P<.02).
The previous report of Kondo et al 16 indicated that smoking may interfere with the Taql B association with plasma HDL. We studied smoking and other lifestyle factors to determine whether this was a generalized effect of lifestyle on HDL or a specific smoking phenomenon. Alcohol consumption, oral contraceptive use, sex, age, and exercise did not disrupt the relation between the Taql B2 restriction site and HDL concentration. However, smoking very clearly did interact with this association (Table 5) Previously, we have suggested 5 that smoking affects plasma lipids via multiple mechanisms. Part of the influence of smoking on HDL cholesterol, and more specifically HDL 2 , could be explained by triglyceridemediated mechanisms. This includes the neutral lipid exchange process that generates triglyceride-enriched HDL that can be lipolyzed to smaller, denser species, which are rapidly cleared from the circulation. 78 However, our earlier data also provided strong evidence for the existence of a triglyceride-independent mechanism by which smoking lowered HDL. We postulate that the Taql CETP gene RFLP effect identified here contributes at least in part to this mechanism. As noted above, we surmise that an effect on CETP activity is not responsible because activities of CETP were not different between groups. Changes in CETP substrate specificity could be potentially responsible for this effect. Alternatively, we postulate that the Taql B RFLP is in linkage disequilibrium with an adjacent critical site. The LCAT gene, which is proximal to the CETP gene on chromosome 16, is a likely candidate. Variation in its activity would be expected to lead to altered HDL 2 formation, which would not be affected by the prevailing plasma triglyceride concentration. However, the genetic distance of approximately 16 centiMorgans 33 between the CETP gene and the LCAT gene is probably too large for the LCAT gene to demonstrate allelic association with the Taql B RFLP. In addition, in our previous study of a selected population, LCAT activity did not differ between the high-and low-HDL groups. 15 The frequency distribution of HDL cholesterol shown in the Figure indicates that not all B2B2 individuals have high HDL cholesterol. Statistical models can be used to test whether a population demonstrates bimodality. Commingling analysis has been used to study the distribution of apolipoprotein B levels in familial combined hyperlipidemia. 34 This involves fitting a mixture of two normal densities and comparing the fit to that of a single normal distribution via a generalized likelihood ratio test. 24 It is usual to fit a mixture of two normals with equal variance, to avoid singularities in the likelihood surface. This model was thought unsuitable for analysis of HDL distribution, as the assumption that the two subpopulations have the same variance is not necessarily true for two populations of HDL. The test for clusters 2425 is sensitive to the alternative hypothesis of two subpopulations with different variances. It might be expected from the skewed distribution of HDL that the population with the higher mean HDL would have a larger variance. There are also theoretical problems with likelihood ratio tests in this context that cast doubt on their validity. 24 The small group size and inherent variation in HDL leave the statistical tests with low power to detect bimodality, and in this case the apparent bimodality failed to reach statistical significance. The data suggest that only one half of the B2B2 homozygotes have a substantially raised HDL cholesterol (>1.6 mmol/L) while 25% of the B1B2 heterozygotes fall into this category. From the observations, we postulate that the HDL-raising effect is present on one half of the B2 alleles detected in our population.
We are presently seeking through family studies better genetic markers that are in closer association with the HDL-raising effect, in the anticipation that these will be in linkage disequilibrium with a true HDL-raising allele.
